Latest Posts
-
3 common mistakes in pharma market access negotiations – and how to avoid them
Market access is often the decisive bottleneck: without successful payer negotiations, even the most innovative product will fail commercially. From my experience, three mistakes repeat again and again: These mistakes cost time, credibility, and millions. With structured frameworks and early preparation, they can be avoided. What has been your experience in payer negotiations?
-
Asia-Pacific BioPharma Insights
Country Spotlight Series: Japan Biotech & Pharma Deep Dive Market Overview Japan is one of the most mature and innovation-driven biotech and pharmaceutical markets, valued at ~$45B in 2023 and projected to reach ~$80–100B by 2030. Key drivers include an aging population, strong R&D ecosystem, and pioneering regulatory frameworks. Innovation Highlights Major Players & Ecosystems…
-
Negotiations in Biotech
In biotech, most negotiations are won or lost long before the first offer is made. After 25+ years as a founder, pharma exec, and investor, I’ve learned this: The real work isn’t at the table – it’s before you even sit down. Too often, teams go in with brilliant science but no clear fallback plan.…